Molecular Partners (MOLN) to Release Quarterly Earnings on Tuesday

Key Points

• Molecular Partners is expected to report Q2 2026 results before the market opens on Tuesday, August 25, with analysts forecasting a loss of $0.45 per share.
• MOLN shares opened at $4.28, with a 52-week range of $3.47 to $5.36 and a market capitalization of approximately $172.6 million. Institutional investors and hedge funds own 26.55% of the company.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $8.38; two analysts rate the stock Buy, one Hold and one Sell.

Molecular Partners (NASDAQ:MOLN - Get Free Report) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 25th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Interested persons may visit the the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 25, 2026 at 3:00 AM ET.

Molecular Partners Stock Performance

Shares of MOLN stock opened at $4.28 on Tuesday. Molecular Partners has a fifty-two week low of $3.47 and a fifty-two week high of $5.36. The stock's fifty day moving average price is $3.99 and its two-hundred day moving average price is $4.23. The company has a market cap of $172.62 million, a PE ratio of -2.20 and a beta of 1.08.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,311 shares of the company's stock, valued at approximately $54,000. Institutional investors and hedge funds own 26.55% of the company's stock.

Analysts Set New Price Targets

MOLN has been the subject of several research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Molecular Partners in a research note on Wednesday, July 8th. HC Wainwright reiterated a "buy" rating on shares of Molecular Partners in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company's technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company's development pipeline spans infectious diseases, ophthalmology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source